carbamates has been researched along with Long QT Syndrome in 11 studies
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Encorafenib (Braftovi) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi)." | 4.02 | Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. ( Lankheet, NAG; Meussen, E; Mian, P; Piersma, D, 2021) |
| " Maintenance dosing was for 9 days." | 2.76 | QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial. ( Aunes-Jansson, M; Bergfeldt, L; Berggren, A; Duris, T; Edvardsson, N; Egstrup, K; Frison, L; Gullestad, L; Johansson, S; Kochmanski, M; Kuśnierz, B; Nielsen, T; Sawicki, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Darpo, B | 2 |
| Sager, PT | 1 |
| Xue, H | 2 |
| Kamin, M | 1 |
| Borin, MT | 1 |
| Barnes, CN | 1 |
| Pendyala, S | 1 |
| Bourdet, DL | 1 |
| Zomorodi, K | 1 |
| Chen, D | 1 |
| Lee, L | 1 |
| Swearingen, D | 1 |
| Carter, LP | 1 |
| Mian, P | 1 |
| Meussen, E | 1 |
| Piersma, D | 1 |
| Lankheet, NAG | 1 |
| Bergenholm, L | 1 |
| Parkinson, J | 1 |
| Mettetal, J | 1 |
| Evans, ND | 1 |
| Chappell, MJ | 1 |
| Collins, T | 1 |
| Rivera-Arconada, I | 1 |
| Vicente-Baz, J | 1 |
| Lopez-Garcia, JA | 1 |
| Maljevic, S | 1 |
| Wuttke, TV | 1 |
| Seebohm, G | 1 |
| Lerche, H | 1 |
| Egstrup, K | 1 |
| Bergfeldt, L | 1 |
| Duris, T | 1 |
| Gullestad, L | 1 |
| Kochmanski, M | 1 |
| Kuśnierz, B | 1 |
| Nielsen, T | 1 |
| Sawicki, S | 1 |
| Aunes-Jansson, M | 1 |
| Edvardsson, N | 1 |
| Frison, L | 1 |
| Johansson, S | 1 |
| Berggren, A | 1 |
| Inglis, F | 1 |
| Preskorn, SH | 1 |
| Borges-Gonzalez, S | 1 |
| Flockhart, D | 1 |
| Walsh, E | 1 |
| Dourish, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placeb[NCT00643448] | Phase 2 | 65 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who had at least one AE according to the definition in the study protocol (NCT00643448)
Timeframe: During treatment days 2-10
| Intervention | Participants (Number) |
|---|---|
| AZD1305 Group A and AZD1305 Group B | 22 |
| Placebo | 13 |
Percentage of twice daily TTM recordings (individual compliance) transmitted and available for analysis (NCT00643448)
Timeframe: During treatment days 1-10
| Intervention | Percentage of recordings analysed (Mean) |
|---|---|
| AZD1305 Group A | 97.4 |
| AZD1305 Group B | 96.4 |
| Placebo | 98.3 |
Population PK model parameter estimates derived from plasma concentrations of AZD1305 (NCT00643448)
Timeframe: During treatment days 1-10
| Intervention | μmol/L (Mean) |
|---|---|
| AZD1305 Group A | 0.41 |
| AZD1305 Group B | 0.45 |
Maximum of all QTcF values obtained for any given patient from randomisation until the intended end of the study drug period, day 10. (NCT00643448)
Timeframe: During treatment days 2-10
| Intervention | ms (Mean) |
|---|---|
| AZD1305 Group A and AZD1305 Group B | 461 |
| Placebo | 427 |
2 reviews available for carbamates and Long QT Syndrome
| Article | Year |
|---|---|
KV7 channelopathies.
Topics: Animals; Carbamates; Channelopathies; Epilepsy; Humans; KCNQ Potassium Channels; Long QT Syndrome; M | 2010 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
Topics: Anti-HIV Agents; Antidepressive Agents; Antiparkinson Agents; Apomorphine; Atazanavir Sulfate; Azabi | 2006 |
5 trials available for carbamates and Long QT Syndrome
| Article | Year |
|---|---|
A Phase 1 Clinical Study Evaluating the Effects of Cenobamate on the QT Interval.
Topics: Adult; Carbamates; Chlorophenols; Double-Blind Method; Humans; Long QT Syndrome; Tetrazoles | 2022 |
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Topics: Adolescent; Adult; Benzamides; Carbamates; Cross-Over Studies; Double-Blind Method; Electrocardiogra | 2020 |
A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
Topics: Adrenergic Uptake Inhibitors; Adult; Carbamates; Cross-Over Studies; Dopamine Uptake Inhibitors; Dos | 2021 |
Predicting QRS and PR interval prolongations in humans using nonclinical data.
Topics: Animals; Anti-Arrhythmia Agents; Azabicyclo Compounds; Carbamates; Dogs; Drug Evaluation, Preclinica | 2017 |
QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Compounds; Carbamates; Delayed-Action | 2011 |
4 other studies available for carbamates and Long QT Syndrome
| Article | Year |
|---|---|
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; C | 2021 |
Targeting Kv7 channels in pain pathways.
Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channe | 2017 |
Rivastigmine and QT interval prolongation.
Topics: Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Neuroprotective Agents; Phenylcarba | 2003 |
Prolonged QT interval with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Male; Neur | 2002 |